Comparing two ways to give HER2-targeted therapy for early breast cancer
Part of Cancer clinical trials.
This trial tests if giving two HER2-targeted drugs together works as well when one is injected under the skin as when it is given through an IV. It aims to find a more convenient option for early-stage breast cancer patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have been diagnosed with HER2-positive breast cancer (a type that has too much HER2 protein).
- Your breast cancer is early-stage or locally advanced (has not spread to distant organs).
- You are not currently pregnant or breastfeeding, and you agree to use birth control if you can get pregnant.
- Your major organs (heart, liver, kidneys, blood) are functioning well enough to handle treatment.
- You have not had prior chemotherapy or radiation for any cancer (except certain treated skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This trial compares two drugs, trastuzumab rezetecan and trastuzumab deruxtecan, given before surgery to shrink HER2-positive breast cancer tumors. It aims to see which drug works better and has fewer side effects, potentially offering a more effective treatment option for patients.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This study compares two treatments for early-stage HER2-positive breast cancer that has not spread to lymph nodes. One treatment is a newer drug called T-DXd, and the other is a combination of two older drugs (THP). The goal is to see which is more effective and safe for patients like you.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.